GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
Global Blood Therapeutics (GBT) will participate in the H.C. Wainwright Global Life Sciences Conference scheduled for March 9, 2021. A presentation by the company's president and CEO, Ted W. Love, M.D., is set to be available at 7:00 a.m. ET. The presentation will be accessible on GBT's website for one month post-event. GBT is dedicated to developing treatments for sickle cell disease and has introduced Oxbryta, the first FDA-approved treatment targeting sickle hemoglobin polymerization.
- Participation in a prominent life sciences conference may boost visibility and investor interest.
- Oxbryta is the first FDA-approved treatment for sickle cell disease, indicating strong market positioning.
- None.
SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) will participate at the H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021. A presentation by Ted W. Love, M.D., president and CEO of GBT, will be available at 7:00 a.m. ET.
The presentation will be available on GBT’s website at www.gbt.com in the Investors section. A replay will be available for one month following the event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact:
Steven Immergut (media)
650.410.3258
simmergut@gbt.com
Courtney Roberts (investors)
650.351.7881
croberts@gbt.com
FAQ
When will Global Blood Therapeutics present at the H.C. Wainwright Global Life Sciences Conference?
What time is the GBT presentation at the conference?
How can I access the GBT presentation?
What is the significance of Oxbryta for Global Blood Therapeutics?
